In light of the rapidly changing coronavirus (COVID-19) situation, Troutman Sanders and Pepper Hamilton have postponed the effective date of their previously announced merger until July 1, 2020. The new firm – Troutman Pepper – will feature 1,100+ attorneys across 23 U.S. offices. Read more.

POWER OF KNOWLEDGE

Insight Center: News

Pepper Hamilton Represents Xenon Pharmaceuticals in License and Collaboration Agreement With Neurocrine Biosciences

12/12/2019
Pepper Hamilton Represents Xenon Pharmaceuticals in License and Collaboration Agreement With Neurocrine Biosciences

Pepper Hamilton represented Xenon Pharmaceuticals in its agreement with Neurocrine Biosciences to develop first-in-class treatments for epilepsy.

Under the terms of the license and collaboration agreement, Neurocrine Biosciences will gain rights to XEN901, a clinical-stage selective Nav1.6 sodium channel inhibitor, being developed for the treatment of epilepsy. Xenon will receive $50 million upfront and up to $1.7 billion in potential development, regulatory and commercial milestone payments across all licensed products, as well as the option to co-fund XEN901.

Xenon is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. Its novel product pipeline of neurology-focused therapies addresses areas of high unmet medical need, with a focus on epilepsy. The company is located in Burnaby, British Columbia, Canada.

Partners Rachael M. Bushey, chair of the Health Sciences Department; N. Nicole Stakleff; and Jennifer L. Porter led the deal for Xenon. The team also included associate Allison P. Nicklin.

Read more about the agreement at https://finance.yahoo.com/news/neurocrine-biosciences-xenon-pharmaceuticals-announce-123010792.html.

Data protection laws have changed, so we have revised our Privacy Policy.

CLOSE